ClinicalTrials.gg
Active, not recruitingNCT03224000Updated Jun 11, 2026

Trial of Magnetic Resonance Imaging Guided Radiotherapy Dose Adaptation in Human Papilloma Virus Positive Oropharyngeal Cancer

A Phase 2 interventional study of Modified Barium Swallow (MBS) and Swallowing Questionnaire in Malignant Neoplasms of Lip Oral Cavity and Pharynx and Oropharyngeal Cancer, sponsored by M.D. Anderson Cancer Center. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-11.

Sponsored by M.D. Anderson Cancer Center · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 26 studies in Oropharyngeal Neoplasms by M.D. Anderson Cancer Center — 4 open to participants now, 10 under way, 1 of them phase 3. Oropharyngeal Neoplasms · M.D. Anderson Cancer Center.

Enrollment
4th of 17
90 · median 25
Started
2018
with 1 other
Phase 2
8 of 26
none open now
Registered
18th of 26
by date

Among the 26 studies in Oropharyngeal Neoplasms by M.D. Anderson Cancer Center, this one is the 4th largest by enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2018, is one of 8 in phase 2, and was the 18th registered.

Oropharyngeal Neoplasms

370 studies on the registry are indexed under Oropharyngeal Neoplasms; 104 are open to participants now.

Browse Oropharyngeal Neoplasms studies →

Open to participants now

4 of the 26 studies in Oropharyngeal Neoplasms by M.D. Anderson Cancer Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 89 Oropharyngeal Neoplasms studies recruiting now, 76 (85%) set no upper age limit and 5 (6%) stop at 75 or younger; none take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Oropharyngeal Neoplasms by M.D. Anderson Cancer Center, or all of them as a file.
02

Study summary

The goal of this clinical research study is to compare the use of MRI simulations to plan different doses of intensity modulated radiotherapy (IMRT) to the standard IMRT dose in patients with low risk human papilloma virus positive oropharyngeal cancer.

This is an investigational study. MRI simulations and radiation therapy are delivered using FDA-approved and commercially available methods. The use of MRI imaging to plan the dose is investigational.

Up to 90 participants will be enrolled in this study. All will take part at MD Anderson.

Read the detailed description

Baseline Visit:

If you are found to be eligible to take part in this study and agree, you will have a baseline visit. The following tests and procedures will be performed:

  • You will have a hearing test.
  • You will have a dental exam. During this exam, your saliva flow will be measured and you will be checked for lockjaw.
  • Your swallowing function will be tested with a special type of x-ray called a modified barium swallow (MBS). During the test, you will eat and drink foods and liquids mixed with a "contrast" chemical called barium that will make your throat more visible in the x-rays. A special x-ray tube will be connected to a television screen to allow the doctor to watch the foods and liquids pass from your mouth and down your throat.
  • You will complete a questionnaire about swallowing that should take about 5 minutes to complete.
  • You will have a video-strobe procedure to check your vocal cords. To perform a video-strobe procedure, a small camera will be inserted into the throat through your nose or mouth. You will be awake for this procedure and the study staff will give you the option of receiving a numbing spray for your nose and/or throat.
  • Photos of the inside of your mouth will be taken to check for mouth sores.
  • You will fill out questionnaires about your quality of life, work status, medical history, smoking status, and any symptoms you may have. Completing these questionnaires should take about 10-15 minutes.

Study Groups:

If you are among the first 15 patients enrolled in the study, you will be in Group 1.

If you join the study after the first 15 patients have enrolled, you will be randomly assigned (as a flip of a coin) to 1 of 2 study groups. This is done because no one knows if one study group is better, the same, or worse than the other group.

  • If you are in Group 1, an MRI will be used to plan your IMRT.
  • If you are in Group 2, you will receive standard-of-care IMRT.

Length of Study Participation:

No matter which group you are in, you may continue receiving radiation therapy for up to 6 ½ weeks. You will no longer be able to take part in this study if the disease gets worse, if intolerable side effects occur, or if you are unable to follow study directions.

Your overall participation on the study will be over after 5 years.

Treatment Planning and Schedule:

You will receive a standard CT simulation which will cover your head and neck for treatment planning. You will also have a PET-CT to check the status of the disease and for treatment planning purposes.

If you are among the first 15 participants or are in Group 1, you also will have an MRI simulation for treatment planning purposes.

All groups will then receive radiation therapy 1 time each day, 5 days a week (Monday through Friday) for up to 33 treatments (about 6 ½ weeks).

Study Visits:

Every week while you are receiving radiation therapy:

  • You will have a physical exam.
  • Blood (about 1-2 tablespoons) will be drawn for routine tests.
  • You will fill out the same questionnaires as before.
  • You will have an MRI.

At Weeks 3 and 6:

  • Photos of the inside of your mouth will be taken to check for mouth sores.
  • You will have a dental exam.

If you are among the first 15 participants or are in Group 1, you will also have the MRI simulation at the end of Weeks 1, 2, 3, and 4 of treatment.

Six (6) weeks after finishing radiation therapy, you will complete the same questionnaires as before.

Within 8-12 weeks after finishing radiation therapy:

  • Photos of the inside of your mouth will be taken to check for mouth sores.
  • You will have a hearing test.
  • If you are among the first 15 participants or are in Group 1, you will have an MRI simulation.

Six (6) months, 1 year, and 2 years after finishing radiation therapy:

  • You will fill out the same questionnaires as before.
  • You will have a mouth exam to check your swallowing function.
  • Photos of the inside of your mouth will be taken to check for mouth sores.
  • You will fill out the same questionnaires as before.
  • You will have a video-strobe procedure to check your vocal cords.
  • At 1 year only, you will have a dental exam and an MBS exam to test your swallowing function.
  • At 1 year and 2 years only, you will also have a hearing test.

Three to six (3-6) months, 1 year, and 18-24 months after finishing radiation therapy:

  • You will have an MBS exam to test your swallowing function.
  • You will fill out the same questionnaires as before.
  • You will have the video-strobe procedure to check your vocal cords.

Two (2) years after finishing radiation therapy and if the disease gets worse, blood (about 3 teaspoons) will be drawn for circulating tumor cells (CTCs). This is a test of how many tumor cells are in the blood.

Five (5) years after finishing radiation therapy, you will have an MBS exam to test your swallowing function and will complete the same questionnaires as before.

If the doctor thinks it is needed during follow-up, you will have a tumor biopsy for tumor marker testing and a CT scan, MRI scan and/or PET/CT scan to check the status of the disease.

Follow-Up Calls:

During the 8-12 weeks while you are recovering from treatment, you will be called or emailed by an automated system every 2 weeks.

This will be to remind you to fill out a web-based form that asks about any side effects you may have had. Completing the form should take about 10-15 minutes each time.

03

Conditions studied

  • Malignant Neoplasms of Lip Oral Cavity and Pharynx
  • Oropharyngeal Cancer

Keywords

  • Malignant neoplasms of lip oral cavity and pharynx
  • Oropharyngeal Cancer
  • Human papilloma virus positive
  • HPV+
  • Squamous cell carcinoma of the oropharynx
  • Squamous cell carcinoma of the tonsil
  • Squamous cell carcinoma of the base of tongue
  • Squamous cell carcinoma of the soft palate
  • Squamous cell carcinoma of the oropharyngeal walls
  • Magnetic Resonance Imaging Guided Radiotherapy
  • Standard of Care Radiotherapy Planning
  • Radiation Therapy
  • Intensity modulated radiotherapy
  • IMRT
  • Modified Barium Swallow
  • MBS
  • Swallowing questionnaire
  • The M.D. Anderson Dysphagia Inventory (MDADI)
  • Symptom questionnaire
  • The M.D. Anderson Symptom Inventory for Head and Neck Cancer (MDASI-HN)
  • Video-Strobe Procedure
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • proven diagnosis of squamous cell carcinoma of the oropharynx (tonsil, base of tongue, soft palate, or oropharyngeal walls). Clinical evidence should be documented, and may consist of imaging, endoscopic evaluation, palpation, and should be sufficient to estimate the size of the primary for purposes of T staging.
  • Age ≥18 years
  • Clinical stage T1-3, N0-2 (AJCC, 8th ed.), with no distant , based on routine staging workup.
  • Positive for HPV by p16 IHC or ISH
  • Lifetime pack-year history of \<10 years, currently non-smoking for at least 5 years.
  • No head and neck surgery of the primary tumor or lymph nodes except for incisional or excisional biopsies.
  • No retropharyngeal nor level IV (or lower) lymphadenopathy (i.e. nodes in level I-III only)
  • (ECOG) = 0, 1, or 2.
  • Dispositioned to photon/proton radiotherapy +/- chemotherapy
  • For females of child-bearing age, a negative pregnancy test

Exclusion criteria

Exclusion Criteria:

  • Patients who have undergone definitive resection of their primary or nodal disease as well as any chemotherapy or radiation therapy for their HNSCC.
  • Pregnant or breast-feeding females
  • uncontrolled major cardiac, respiratory, renal, hepatic, gastrointestinal or hematologic disease but not limited to:
  • Symptomatic congestive heart failure, unstable angina, or cardiac dysrhythmia not controlled by pacer device
  • Myocardial infarction within 3 months of registration
  • to MR imaging (e.g. implanted metallic prostheses, defibrillators, stimulators, pacemakers, or neurotransmitters) per institutional policy on management of patients with internal and external medical devices.
  • History of claustrophobia
  • Having an estimated (GFR) \< 40ml/min/1.73m2
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
90 participants (actual)

Study arms

  • Experimental
    MRI Guided Intensity Modulated Radiotherapy (IMRT)

    Modified barium swallow (MBS) performed at baseline and at 6 months, 2 years, and 5 years after finishing radiation therapy. Swallowing questionnaire completed at baseline, every week while receiving radiation therapy, and at 6 months, 2 years, and 5 years after finishing radiation therapy. Symptom questionnaire completed at baseline, every week while receiving radiation therapy, and at 6 months, 2 years, and 5 years after finishing radiation therapy. Video-strobe procedure performed at baseline, at week 3 during radiation therapy, and at 6 months, 2 years, and 5 years after finishing radiation therapy. IMRT planned with MRI guidance. Participants receive an individualized prescription of up to 70 Gy in 33 fractions with radiation therapy (RT) given once daily, 5 days a week, over 6 weeks and 3 days.

    Procedure: Modified Barium Swallow (MBS) · Behavioral: Swallowing Questionnaire · Behavioral: Symptom Questionnaire · Procedure: Video-Strobe Procedure · Procedure: MRI Guided Intensity Modulated Radiotherapy (IMRT) Planning · Radiation: Intensity Modulated Radiotherapy (IMRT)

  • Active comparator
    Standard-of-Care Intensity Modulated Radiotherapy (IMRT)

    Modified barium swallow (MBS) performed at baseline and at 6 months, 2 years, and 5 years after finishing radiation therapy. Swallowing questionnaire completed at baseline, every week while receiving radiation therapy, and at 6 months, 2 years, and 5 years after finishing radiation therapy. Symptom questionnaire completed at baseline, every week while receiving radiation therapy, and at 6 months, 2 years, and 5 years after finishing radiation therapy. Video-strobe procedure performed at baseline, at week 3 during radiation therapy, and at 6 months, 2 years, and 5 years after finishing radiation therapy. IMRT planned by standard-of-care. Participants receive an individualized prescription of up to 70 Gy in 33 fractions with radiation therapy (RT) given once daily, 5 days a week, over 6 weeks and 3 days.

    Procedure: Modified Barium Swallow (MBS) · Behavioral: Swallowing Questionnaire · Behavioral: Symptom Questionnaire · Procedure: Video-Strobe Procedure · Procedure: Standard-of-Care Intensity Modulated Radiotherapy (IMRT) Planning · Radiation: Intensity Modulated Radiotherapy (IMRT)

Interventions

  • ProcedureModified Barium Swallow (MBS)

    Modified barium swallow (MBS) performed at baseline and at 6 months, 2 years, and 5 years after finishing radiation therapy.

  • BehavioralSwallowing Questionnaire

    Swallowing questionnaire completed at baseline, every week while receiving radiation therapy, and at 6 months, 2 years, and 5 years after finishing radiation therapy.

    Also known as: The M.D. Anderson Dysphagia Inventory (MDADI)

  • BehavioralSymptom Questionnaire

    Symptom questionnaire completed at baseline, every week while receiving radiation therapy, and at 6 months, 2 years, and 5 years after finishing radiation therapy.

    Also known as: The M.D. Anderson Symptom Inventory for Head and Neck Cancer (MDASI-HN)

  • ProcedureVideo-Strobe Procedure

    Video-strobe procedure to check vocal cords performed at baseline, at week 3 during radiation therapy, and at 6 months, 2 years, and 5 years after finishing radiation therapy.

  • ProcedureMRI Guided Intensity Modulated Radiotherapy (IMRT) Planning

    IMRT planned with MRI guidance.

  • ProcedureStandard-of-Care Intensity Modulated Radiotherapy (IMRT) Planning

    IMRT planned by standard-of-care.

  • RadiationIntensity Modulated Radiotherapy (IMRT)

    Participants receive an individualized prescription of up to 70 Gy in 33 fractions with radiation therapy (RT) given once daily, 5 days a week, over 6 weeks and 3 days.

    Also known as: Radiation therapy, XRT

06

What researchers measure

Primary outcomes

  1. Locoregional Control

    Relapse defined as reappearance of tumor after complete response. If possible, relapse confirmed by biopsy.

    Time frame: 6 months post radiation therapy

  2. Composite Dysphagia Outcome Determined by PEG Tube Dependence at Last Follow-Up

    Composite dysphagia outcome calculated based on objective measurements of severe dysphagia. These include: 1) PEG tube dependence at last follow-up; 2) trace or frank aspiration seen on modified barium swallow study; 3) diagnosis of aspiration pneumonia; 4) presence of pharyngoesophageal structure on modified barium swallow study or endoscopy with subsequent need for dilation.

    Time frame: 6 months post radiation therapy

  3. Composite Dysphagia Outcome Determined by Trace or Frank Aspiration Seen on Modified Barium Swallow Study

    Composite dysphagia outcome calculated based on objective measurements of severe dysphagia.

    Time frame: 6 months post radiation therapy

  4. Composite Dysphagia Outcome Determined by Diagnosis of Aspiration Pneumonia

    Composite dysphagia outcome calculated based on objective measurements of severe dysphagia.

    Time frame: 6 months post radiation therapy

  5. Composite Dysphagia Outcome Determined by Presence of Pharyngoesophageal Structure on Modified Barium Swallow Study

    Composite dysphagia outcome calculated based on objective measurements of severe dysphagia.

    Time frame: 6 months post radiation therapy

  6. Composite Dysphagia Outcome Determined by Presence of Pharyngoesophageal Structure on Endoscopy with Subsequent Need for Dilation

    Composite dysphagia outcome calculated based on objective measurements of severe dysphagia.

    Time frame: 6 months post radiation therapy

Secondary outcomes

  1. Overall Survival

    Overall survival, calculated as time from diagnosis to either death or last follow-up, with death serving as an event and all others censored.

    Time frame: Start of treatment up to 5 years

  2. Progression-Free Survival

    Progression-free survival, calculated as time from diagnosis to either death or detection of recurrent disease after an interval without radiographic of clinically evident disease (whichever is earlier), with death or recurrence detection serving as an event and all others censored.

    Time frame: Start of treatment up to 5 years

  3. Distant Metastasis-Free Survival

    Distant metastasis-free survival, calculated as time from diagnosis to either death or detection of disease outside of the head and neck after an interval without radiographic of clinically evident disease (whichever is earlier), with death or metastasis detection serving as an event and all others censored.

    Time frame: Start of treatment up to 5 years

  4. Patient Reported Outcome (PRO) Measures of Symptoms Using MD Anderson Symptom Inventory (MDASI)

    Patient Reported Outcome (PRO) measures of symptoms using MD Anderson Symptom Inventory (MDASI)

    Time frame: Baseline up to 2 years after radiation therapy

  5. Physician-Reported Toxicity

    Physician-reported toxicity, defined as any grade 3-4 adverse events using Common Terminology Criteria for Adverse Events (CTCAE)-4.0.

    Time frame: Weekly during radiation therapy up to 2 years after radiation therapy

  6. Patient Reported Outcome (PRO) Measures of Symptoms Using MD Anderson Dysphagia Inventory (MDADI)

    Time frame: Baseline up to 2 years after radiation therapy

  7. Patient Reported Outcome (PRO) Measures of Symptoms Using FACT-HN

    Time frame: Baseline up to 2 years after radiation therapy

  8. Patient Reported Outcome (PRO) Measures of Symptoms Using Xerostomia and Health Questionnaire (EQ-5D-3L)

    Time frame: Baseline up to 2 years after radiation therapy

  9. Patient Reported Outcome (PRO) Measures of symptoms Using Performance Status Scale-HN

    Time frame: Baseline up to 2 years after radiation therapy

  10. Patient Reported Outcome (PRO) Measures of symptoms Using Work Productivity and Activity Impairment Questionnaire

    Time frame: Baseline up to 2 years after radiation therapy

07

Study locations

1 site
08

References and documents

Publications

  • Bahig H, Yuan Y, Mohamed ASR, Brock KK, Ng SP, Wang J, Ding Y, Hutcheson K, McCulloch M, Balter PA, Lai SY, Al-Mamgani A, Sonke JJ, van der Heide UA, Nutting C, Li XA, Robbins J, Awan M, Karam I, Newbold K, Harrington K, Oelfke U, Bhide S, Philippens MEP, Terhaard CHJ, McPartlin AJ, Blanchard P, Garden AS, Rosenthal DI, Gunn GB, Phan J, Cazoulat G, Aristophanous M, McSpadden KK, Garcia JA, van den Berg CAT, Raaijmakers CPJ, Kerkmeijer L, Doornaert P, Blinde S, Frank SJ, Fuller CD. Magnetic Resonance-based Response Assessment and Dose Adaptation in Human Papilloma Virus Positive Tumors of the Oropharynx treated with Radiotherapy (MR-ADAPTOR): An R-IDEAL stage 2a-2b/Bayesian phase II trial. Clin Transl Radiat Oncol. 2018 Aug 24;13:19-23. doi: 10.1016/j.ctro.2018.08.003. eCollection 2018 Nov. PubMed 30386824 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2018 (actual). Primary completion is estimated for Dec 2026, 107 months after the start.

Of 63 non-industry phase 2 interventional studies under Oropharyngeal Neoplasms, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 49 and three quarters within 99. This study's planned 107 months is above that.

Counting every sponsor, half of 64 studies reached it within 63 months; a quarter within 49 and three quarters within 99.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2017
First posted
Jul 21, 2017
StartActual
Jan 17, 2018
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Jun 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03224000
Responsible party
Sponsor
First posted
Jul 21, 2017
Start date
Jan 17, 2018
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jun 11, 2026

Study contacts

Clifton Fuller, MD, PHD
principal investigator · M.D. Anderson Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion